The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review Dustin H. MarksJean-Phillip OkhovatMaryanne M. Senna Review 26 February 2019 Pages: 267 - 276
The next generation personalized models to screen hidden layers of breast cancer tumorigenicity F. AfzaliP. AkbariM. Gardaneh Review 27 February 2019 Pages: 277 - 286
Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up Sherry X. YangEric C. Polley Preclinical study Open access 12 February 2019 Pages: 287 - 295
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion Landry K. KamdemJingyue XiDaniel L. Hertz Preclinical study 12 February 2019 Pages: 297 - 303
The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast Ulrik NarbeMartin SjöströmMårten Fernö Preclinical study Open access 22 February 2019 Pages: 305 - 316
Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach Mariana Ferreira LealBen P. HaynesMitch Dowsett Preclinical study Open access 22 February 2019 Pages: 317 - 326
SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma Emily A. BossartNilgun TasdemirSteffi Oesterreich Preclinical study 23 February 2019 Pages: 327 - 337
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer Jangsoon LeeBora LimNaoto T. Ueno Preclinical study 02 March 2019 Pages: 339 - 351
ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer Zhanwei WangDionyssios KatsarosHerbert Yu Preclinical study 04 March 2019 Pages: 353 - 368
Breast sensibility after mastectomy and implant-based breast reconstruction E. BijkerkS. M. J. van KuijkS. M. H. Tuinder Clinical trial Open access 12 February 2019 Pages: 369 - 378
Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit Alexandre de NonnevilleCamille JauffretGilles Houvenaeghel Clinical Trial 13 February 2019 Pages: 379 - 387
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study R. WuerstleinR. KatesWSG-PRIMe investigators in Germany, Austria, Switzerland Clinical trial Open access 22 February 2019 Pages: 389 - 399
Loss of HER2 after HER2-targeted treatment Tanja IgnatovFranceska GorbunowAtanas Ignatov Clinical trial 26 February 2019 Pages: 401 - 408
Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma Shearwood McClelland IIIJess HatfieldTimur Mitin Clinical trial 28 February 2019 Pages: 409 - 418
Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval Ingrid G. M. PoodtRobert-Jan Schipperthe Sentinel Node And Recurrent Breast Cancer (SNARB) Research Group Clinical trial Open access 06 April 2019 Pages: 419 - 428
The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients M. L. GregorowitschA. GhedriUMBRELLA study group Epidemiology Open access 12 February 2019 Pages: 429 - 441
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers Joanne KotsopoulosJan Lubinskithe Hereditary Breast Cancer Clinical Study Group Epidemiology 12 February 2019 Pages: 443 - 449
Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material A. M. Sofie BerghuisCarolien H. M. van DeurzenMaarten J. IJzerman Epidemiology Open access 13 February 2019 Pages: 451 - 458
A high-risk luminal A dominant breast cancer subtype with increased mobility Liping GuoGuoji ChenKaitai Zhang Epidemiology Open access 19 February 2019 Pages: 459 - 472
Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis Stephanie R. RiceSteven J. FeigenbergElizabeth M. Nichols Epidemiology 22 February 2019 Pages: 473 - 478
Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors Gitana Maria AcetoKhalid Dafaallah AwadelkarimRenato Mariani-Costantini Epidemiology Open access 22 February 2019 Pages: 479 - 485
Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands Carmen van DooijeweertIvette A. G. DeckersPaul J. van Diest Epidemiology Open access 01 March 2019 Pages: 487 - 497
Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany Daniela DoegeMelissa Suk-Yin ThongVolker Arndt Epidemiology 02 March 2019 Pages: 499 - 510
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients Chara StavrakaAthanasios PouptsisJanine Mansi Brief report Open access 12 February 2019 Pages: 511 - 517
Validation of the breast cancer surveillance consortium model of breast cancer risk Jeffrey A. TiceMichael C. S. BissellKarla Kerlikowske Brief Report 22 February 2019 Pages: 519 - 523
Corneal features in trastuzumab emtansine treatment: not a rare occurrence Els DeklerckHannelore DenysElke O. Kreps Brief Report 28 February 2019 Pages: 525 - 530